Lantern Pharma (LTRN) Competitors $3.52 +0.03 (+0.86%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. TLSA, NKTX, CHRS, LYEL, SCPH, LRMR, CTNM, KRRO, OGI, and EPRXShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Tiziana Life Sciences (TLSA), Nkarta (NKTX), Coherus BioSciences (CHRS), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Korro Bio (KRRO), Organigram (OGI), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Tiziana Life Sciences Nkarta Coherus BioSciences Lyell Immunopharma scPharmaceuticals Larimar Therapeutics Contineum Therapeutics Korro Bio Organigram Eupraxia Pharmaceuticals Tiziana Life Sciences (NASDAQ:TLSA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do analysts prefer TLSA or LTRN? Lantern Pharma has a consensus target price of $25.00, suggesting a potential upside of 610.23%. Given Lantern Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Lantern Pharma is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lantern Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor TLSA or LTRN? In the previous week, Tiziana Life Sciences had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 1.89 beat Tiziana Life Sciences' score of 0.51 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Overall Sentiment Tiziana Life Sciences Positive Lantern Pharma Very Positive Do insiders & institutionals believe in TLSA or LTRN? 28.6% of Lantern Pharma shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 7.3% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, TLSA or LTRN? Tiziana Life Sciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Does the MarketBeat Community favor TLSA or LTRN? Tiziana Life Sciences received 83 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 76.47% of users gave Lantern Pharma an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote. CompanyUnderperformOutperformTiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Lantern PharmaOutperform Votes1376.47% Underperform Votes423.53% Which has better earnings and valuation, TLSA or LTRN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$17.69MN/AN/ALantern PharmaN/AN/A-$15.96M-$1.93-1.82 Is TLSA or LTRN more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Lantern Pharma N/A -56.91%-51.17% SummaryLantern Pharma beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks. Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.96M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-1.987.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.946.516.774.25Net Income-$15.96M$143.21M$3.22B$248.23M7 Day Performance-5.63%3.97%3.26%3.29%1 Month Performance-0.85%0.37%0.02%2.42%1 Year Performance-30.98%2.60%18.01%5.54% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma2.4795 of 5 stars$3.52+0.9%$25.00+610.2%-31.0%$37.96MN/A-1.9820Upcoming EarningsNews CoverageTLSATiziana Life Sciences0.5129 of 5 stars$1.13+5.6%N/A+110.0%$132.04MN/A0.008Short Interest ↑News CoverageNKTXNkarta2.832 of 5 stars$1.85+2.2%$14.86+703.1%-68.3%$131.27MN/A-0.98140Upcoming EarningsPositive NewsCHRSCoherus BioSciences3.532 of 5 stars$1.06-5.4%$5.38+407.1%-47.4%$129.81M$266.96M-13.25330Upcoming EarningsAnalyst ForecastGap DownLYELLyell Immunopharma3.3977 of 5 stars$0.44+0.9%$1.00+128.5%-78.1%$129.25M$61,000.00-0.55270Upcoming EarningsNews CoveragePositive NewsSCPHscPharmaceuticals3.7171 of 5 stars$2.56-0.4%$14.00+446.9%-43.0%$128.73M$36.33M-1.3530News CoveragePositive NewsLRMRLarimar Therapeutics2.035 of 5 stars$2.01+5.2%$19.63+876.4%-61.5%$128.70MN/A-1.7530Earnings ReportUpcoming EarningsOptions VolumeNews CoveragePositive NewsCTNMContineum Therapeutics1.9406 of 5 stars$4.95+7.1%$24.80+401.0%-73.7%$128.07M$50M-1.0131News CoverageKRROKorro Bio1.4964 of 5 stars$13.64-1.9%$120.43+782.9%-68.7%$128.07M$2.27M-1.4570Analyst ForecastNews CoverageOGIOrganigram0.8351 of 5 stars$1.00-6.5%N/A-45.3%$126.26M$166.12M-2.63860EPRXEupraxia Pharmaceuticals2.9612 of 5 stars$3.48+5.8%$10.50+201.7%+49.6%$124.76MN/A-4.8329Gap UpHigh Trading Volume Related Companies and Tools Related Companies TLSA Alternatives NKTX Alternatives CHRS Alternatives LYEL Alternatives SCPH Alternatives LRMR Alternatives CTNM Alternatives KRRO Alternatives OGI Alternatives EPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LTRN Stock Free LTRN Stock Alerts